Upcoming Webinar
A Combination Treatment for Patients with Advanced Renal Cell Carcinoma
Date: June 16, 2026 | 2:00 PM
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Cabozantinib (CABOMETYX®) plus nivolumab (OPDIVO®) remains an important first-line treatment option for advanced renal cell carcinoma. For care teams, treatment management extends beyond selecting a regimen.
In this session, Jennifer Hasiak, PharmD (Hematology & Oncology Consultants), explores clinical and treatment management considerations for patients receiving cabozantinib plus nivolumab.
What we’ll cover:
- What the efficacy and safety data tell us about cabozantinib plus nivolumab
- Considerations for monitoring patients throughout treatment
- Approaches to managing treatment-related adverse reactions
- Strategies for patient education and support
- Resources available to patients, caregivers, and care teams
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Additional Upcoming Webinars
June 16, 2026 | 2:00 PM